
What’s Ahead for Alzheimer’s Drugs in 2025
Learn about 2025’s newly approved or potential Alzheimer’s drugs. These include Leqembi, Kisunla, Remternetug, Semaglutide, Trontinemab and Bepranemab.

Learn about 2025’s newly approved or potential Alzheimer’s drugs. These include Leqembi, Kisunla, Remternetug, Semaglutide, Trontinemab and Bepranemab.

Leqembi and Kisunla are the new Alzheimer’s immunotherapies. A loss of brain volume associated with these immunotherapies may be caused by the removal of amyloid plaques, rather than the loss of neurons or brain tissue. A new study sheds light on what’s going on.

A trio of key studies identified predictors of dementia risk, the benefits of detecting cognitive impairment early and identified barriers to routine cognitive screening in older adults, such as cost. See their recommendations.

How much protection can frequent spatial processing tasks offer against Alzheimer’s? Researchers in The British Medical Journal investigate.

A new study shows ultrasound improves memory even when amyloid plaque levels don’t improve. (Amyloid is the culprit behind Alzheimer’s.) Could ultrasound be the missing piece in the Alzheimer’s puzzle?

Ketones are a backup source of energy for neurons. Now, exciting research reveals bigger news: Ketone esters help clear misfolded proteins in animal models of aging and Alzheimer’s.

Europe originally said Lecanemab (Brand-name Leqembi) was too risky to approve. Now they are recommending marketing it. Why the change of heart?

Japanese researchers develop a simple test for diagnosing Alzheimer’s quickly, easily, with 83% accuracy.

The European Medicines Agency (EMA) recommended approving Leqembi® (generic lecanemab) for Alzheimer’s. Originally skeptics, learn how the “Clarity AD” trial helped change their mind.

See Lady Liv, the first AI avatar born from real people’s lived experiences with dementia. Watch ‘Liv’ help those recently diagnosed, by answering questions only a peer who shares the experience of Alzheimer’s would know.

New long-term data suggests lecanemab could delay the shift from mild memory loss to moderate Alzheimer’s by up to eight years—offering families precious time and renewed hope.

Strengthening social connections may offer a surprising boost to long-term brain health.

When Memory Loss Becomes Invisible to Those Who Need Help Most

It is one of the most beautiful Compensations of this life thatNo man can sincerely try to help anotherWithout helping himself.

What are the early symptoms of Alzheimer’s? When to get a professional evaluation.

SHORT-TERM MEMORY lapses are obvious signs of Alzheimer’s, but other tell-tale signals begin to show much earlier. Learn how to look for semantic impairments, such as simple questions about size.

Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?
No spam, only news and updates.


